Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

SPDR Series Trust SPDR S&P Biotech ETF (NY: XBI )

92.55 -0.43 (-0.46%)
Streaming Delayed Price Updated: 3:53 PM EST, Jan 24, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about SPDR Series Trust SPDR S&P Biotech ETF

< Previous 1 2
...
5 6 7 8 9 10 11 12 Next >
“Wrong Side Of The Wave” Stock Market (And Sentiment Results)
Spreads peaked at 6% in early July and have now rolled over to 4.24% (176 bps) in the past 5 weeks alone. This looks more like a small “aftershock” than a new earthquake. 
Via Talk Markets
Check your Portfolio for Small Cap Weighting: Growth, Innovation or Speculation?
The SPDR S&P Biotech ETF remains our key indicator for small cap biotechs. It is up 14.55% over one month at $93.78 but is still down 16% YTD. The Russell 2000 is up 16.5% over one month mirroring... 
Via Talk Markets
Exploding Interest Rates May Finally Suck Stocks Lower
Stocks moved lower today, despite moving sharply higher to start. 
Via Talk Markets
Small Cap Biotechs Perk Up On Dealmaking
With M&A picking up we would think smaller deals make sense for large cap biopharma to expand pipelines and complement technology. 
Via Talk Markets
Stocks Stall On August 1, As Stagflation Appears To Have Finally Arrived
Today financial conditions tightened some, with the IEF/LQD ratio moving up by 45 bps. 
Via Talk Markets
AskSlim Market Week - Friday, July 22
Technical and cycle analysis, and market commentary. 
Via Talk Markets
UUP ETF – Trade Setup Of The Week
UUP has been trending higher while the rest of the stock and bond market has been falling. 
Via Talk Markets
Time For A Pause Or Mild Pullback?
The stock market has had a nice little rally over the past week. It still needs to clear some upside to see that defined higher highs and higher lows, but let’s not be greedy here. 
Via Talk Markets
Bullish Expanding Falling Wedge
I’ve been mentioning lately that I thought that many areas in the PM complex could be building out a potential bullish expanding falling wedge. This is a bullish pattern that few if any chartists... 
Via Talk Markets
The 3 Best Market Sectors for the Second Half of 2022
Compelling themes will drive a recovery in some sectors over the second half of 2022. The following are the best market sectors to buy into. 
Via InvestorPlace
Chris Stapleton “Starting Over” Stock Market (And Sentiment Results)
The “hard roads” are stepping in at times like these when others are selling in the hole. We saw it with China stocks bottoming in March. We saw it with Biotech bottoming in May. We may now be seeing... 
Via Talk Markets
Broad Market Rallies Despite Currency Headwinds
HealthCare and Biotech shares have been strong over the past 30 days as investors have sought trades away from macro and earnings concerns. In times of volatility portfolio strategists may re-balance... 
Via Talk Markets
Stocks Dump Hard After Morning Rally Attempt Fails On July 18
Stocks had an exciting day, starting higher and finishing lower. The S&P 500 was up around 1% to start the day and finished the day lower by 85 bps. 
Via Talk Markets
Nasdaq Flashes A Stealth Buy Signal: What’s Next?
The Nasdaq is now trading above its 20-day exponential moving average. 
Via Talk Markets
7 Biotech Stocks to Buy for Q3
These biotech stocks could be good buys due for a few reasons, including great R&D pipelines and treatments with promising market potential. 
Via InvestorPlace
Small Cap Biotech Stocks Are Trending Well
Despite a little weakness last week, small cap biotechs are trending well for traders. For investors entering the trade on July 5 all of our. focus stocks are up except ChemoCentryx. 
Via Talk Markets
CNBC's Final Trades: Biotech, CVS Health, Walt Disney And This Stock That Could Benefit From Taiwan Semiconductor's Earnings Release
On CNBC’s “Halftime Report Final Trades,” Bryn Talkington of Requisite Capital Management chose SPDR S&P Biotech ETF (NYSE: XBI). 
Via Benzinga
CNBC Fast Money Favorites: AMD, CVS, And One Of The Worst Performers In The S&P 500 Today
CNBC’s "Fast Money: Halftime Report" delivers market-moving news to investors. The commentary delivered by hosts of the show often moves the stocks mentioned. The... 
Via Benzinga
5 ETFs Riding High On The Biotech Comeback
The high-growth biotech segment has borne the maximum brunt of the broader market sell-off. 
Via Talk Markets
7 Best Biotech Stocks to Buy in July 2022
The best biotech stocks to buy are a lot like the best computer stocks 40 years ago; the biggest similarity is how hard they are to predict. 
Via InvestorPlace
3 Biotech Stocks to Sell Now
These biotech stocks remain vulnerable to more downside. Their charts remain broken and resistance looms ominously overhead. 
Via InvestorPlace
Attention Biotech Investors: Mark Your Calendar For These July PDUFA Dates
The biotech sector is poised to end June on a positive note, despite largely disappointing regulatory decisions scheduled during the month, thanks to a reversal in broader market sentiment. 
Via Benzinga
3 Stocks to Sell Now
Equities suffer from the highest inflation readings of a generation. Here's a trio of S&P 500 stocks to sell before things get worse. 
Via InvestorPlace
7 Biotech Stocks With Key Catalysts Coming in July
Biotech stocks have had a rocky few months, but many are on the mend. These picks should provide investors both flexibility and growth. 
Via InvestorPlace
U.S. Weekly FundFlows Insight Report: Sector-Energy Funds Report $1.3 Billion in Outflows, Fourth Largest on Record
During fund-flows week ended June 22, 2022, investors were overall net sellers of fund assets (including both conventional funds and ETFs) for the second straight week, withdrawing a net $20.1... 
Via Talk Markets
3 Beaten-Down ETFs to Buy Before They Rebound
The charts are improving for these fallen angels, and that makes them all top ETFs to buy for the back half of the year. 
Via InvestorPlace
“Should’ve Been Me” Stock Market (And Sentiment Results)
In this week’s AAII Sentiment Survey result, bullish percent ticked down to 18.2% this week from 19.4% last week. 
Via Talk Markets
Option Bears Reloading as Bulls Feeling Spry
As the bulls have their moment, the bears are adding bearish options positions and rolling up into the strength. 
Via Talk Markets
Stock Drop On June 16, But A Rally May Be Coming After Options Expiration
Another miserable day for stocks, with the S&P 500 dropping 3.25% 
Via Talk Markets
Do Crispr And Vertex Have A 'Functional Cure' For Blood Diseases?
Crispr and Vertex tested their gene-edited drug in two blood diseases. 
Via Investor's Business Daily
< Previous 1 2
...
5 6 7 8 9 10 11 12 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.